Latest filing published 13 Jun 2022 for Neuropathix, INC., €234.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Dean Petkanas: trading record in brief
Dean Petkanas, listed as chief executive, appears in our data through filings on Neuropathix, Inc. shares, published by SEC (Form 4). We count 21 filings; the first trade dates from 14 August 2019 and the latest from 13 June 2022.
The open-market record consists of 12 sales worth €112k, with no purchase. Besides market trades, the filings include 5 share grants. 2022 to date brings no purchases and 11 sales.
The latest filing, published on 13 June 2022, reports an open-market sale of €935 in Neuropathix, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Dean Petkanas
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 10,000 shares@ US$0.0250.3% of flowCommon StockSEC:0001607062-22-000413:0
- 100,000 shares@ US$0.0263.0% of flowCommon StockSEC:0001607062-22-000403:0
- 89,000 shares@ US$0.0474.5% of flowCommon StockSEC:0001607062-22-000004:0
- 1,875,000 shares@ US$0.04892.2% of flowCommon StockSEC:0001607062-21-000244:0
4 of 4 declarations